Marker Therapeutics Hosts Expert Roundtable on Next-Generation Cell Therapies – MAR-T Platform Takes Center Stage

Leading Immuno-Oncology Experts to Evaluate CAR-T Progress and Alternative Approaches on May 28

Marker Therapeutics, a Houston-based clinical-stage immuno-oncology company, is convening a distinguished panel of cell therapy specialists for an online discussion examining the evolution of chimeric antigen receptor T-cell treatments and emerging therapeutic alternatives. The session, scheduled for May 28, 2025 at 11:00 a.m. EDT, will explore how current approved therapies have performed against initial expectations and what innovations might address existing clinical gaps.

The Case for Next-Generation T-Cell Approaches

Seven years have elapsed since the FDA approved the first CD19-targeted CAR-T therapies, marking a significant milestone in cancer treatment. However, clinical experience has revealed persistent challenges—including limited applicability across patient populations, manufacturing complexity, and response durability issues. During the webcast, Dr. Juan Vera, President and Chief Executive Officer of Marker Therapeutics, will introduce the company’s MAR-T cell platform as a counterpoint to engineered CAR-T approaches. This multi-antigen recognizing technology represents an alternative pathway that circumvents certain engineering requirements while maintaining therapeutic breadth.

Assembled Expertise in Immuno-Oncology

The roundtable brings together pioneers whose work has fundamentally shaped cellular immunotherapy:

Dr. Helen Heslop from Baylor College of Medicine and Director of the Center for Cell and Gene Therapy will address why current CAR-T strategies fall short of their therapeutic promise. Dr. Malcolm Brenner, Founding Director of the same center and Distinguished Service Professor, will discuss potential solutions to overcome existing limitations. Dr. Geoffrey Shouse from City of Hope and Dr. Manali Kamdar from the University of Colorado will contribute their clinical perspectives to the discussion.

One-Hour Interactive Program Structure

The session runs from 11:00 a.m. to 12:00 p.m. EDT with the following flow:

Opening remarks (5 minutes) will set the context, followed by presentations on CAR-T shortcomings and proposed solutions. Dr. Vera will then present Marker’s MAR-T approach during a dedicated 5-minute segment. A 30-minute roundtable conversation will allow the panelists, moderated by Dr. Richard Marfuggi of the WBB Research Institute, to explore these topics in depth. The program concludes with 10 minutes for audience questions, enabling global participants to engage with the experts.

About Marker Therapeutics and Its MAR-T Platform

Marker Therapeutics develops next-generation T cell immunotherapies for blood cancers and solid tumors. Founded at Baylor College of Medicine, the company has advanced clinical programs with data from over 200 patients demonstrating tolerability and sustained responses. The company’s autologous and allogeneic MAR-T cell products reflect a distinct technical approach—one grounded in decades of cell therapy research but differentiated from CAR-engineered strategies.

Interested researchers and clinicians can register for the webcast through the event portal. For additional information, Marker Therapeutics can be reached at +1 (713) 400-6400 or through their investor relations department.